Full Breakdown
Johnson & Johnson’s Caplyta Meets Primary Endpoint in Late-Stage Bipolar Mania Trial
By Drooid · · How we work
Phase 3 Trial Demonstrates Statistically Significant Mania Reduction
On September 22, 2026, Johnson & Johnson announced that its investigational drug Caplyta (lumateperone) achieved its primary goal in a pivotal Phase 3 study of adults experiencing acute manic episodes of bipolar I disorder. The double-blind, randomized trial compared once-daily 42 mg Caplyta with placebo over three weeks. Patients receiving Caplyta showed a 4.8-point greater reduction in Young Mania Rating Scale (YMRS) total scores versus placebo at Week 3, with an effect size of -0.69 and a p-value < 0.0001. Improvements were evident as early as Day 3 and persisted through the three-week period.
Background & Context
Caplyta is already approved by the U.S. Food and Drug Administration for depressive episodes of bipolar I or II disorder, schizophrenia, and as adjunctive therapy for major depressive disorder.
Data & Statistics
- YMRS reduction: 4.8-point advantage for Caplyta vs. placebo at Week 3.
- Effect size: –0.69 (p < 0.0001).
- Clinical response rate (>= 50 % symptom reduction): 45.8 % with Caplyta vs. 20.9 % with placebo.
- Overall illness severity (CGI-S): Least-squares mean difference of –0.5 favoring Caplyta.
- Adverse events >= 5 % and >= 2× placebo: Dry mouth (7.9 % vs. 3.4 %) and nausea (7.9 % vs. 2.3 %).
- Safety profile: Consistent with Caplyta’s established tolerability; low discontinuation rates reported.
The findings were presented at the 2026 Psych Congress Annual Meeting, which began September 15 in New Orleans and Los Angeles.
Official Statements & Responses
Johnson & Johnson’s press release highlighted the rapid onset of benefit, the durability of response through Week 3, and the drug’s safety consistency with prior indications.
Market Impact & Projections
UBS reiterated a Buy rating on Johnson & Johnson stock and raised its price target to $320, citing the trial’s positive data as a catalyst for the Caplyta franchise. The analyst projected long-term peak sales exceeding $5 billion, modeling 2033 sales of $4.3 billion and emphasizing limited generic competition for at least a decade.
Following the announcement, Johnson & Johnson shares closed at $269.99 on September 21, 2026, up 0.86 %, outperforming the broader S&P 500. The market response reflected investor optimism about an expanded label and the drug’s revenue potential.
Verbatim Quotes
- “Mania is among the most dangerous and worrisome phases of bipolar disorder, and treating it effectively takes more than partial or temporary relief of symptoms. It means bringing the episode itself under control as quickly as possible,” — Michael E. Thase
- “Bipolar I disorder is a lifelong, cycling illness, and managing it means navigating both manic and depressive episodes over time, each with distinct treatment needs,” — Jane Tiller, Vice President, Global Head of Development, Neuroscience, Johnson & Johnson
What’s Next
A second Phase 3 study of Caplyta for bipolar mania has completed enrollment; data analysis is currently underway. Johnson & Johnson indicated that regulatory filing timelines will be communicated after the second study’s results are reviewed.